- Home
- FAX vs STTK Comparison
FAX vs STTK Comparison
Compare FAX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | STTK |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.9M | 538.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FAX | STTK |
|---|---|---|
| Price | $14.54 | $5.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 160.4K | ★ 516.2K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.18 | $0.71 |
| 52 Week High | $16.95 | $8.33 |
Technical Indicators
Market Signals| Indicator | FAX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 39.16 |
| Support Level | $14.46 | $5.85 |
| Resistance Level | $15.53 | $6.81 |
| Average True Range (ATR) | 0.25 | 0.60 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 10.69 | 9.90 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.